JonesResearch raised the firm’s price target on Trevi Therapeutics (TRVI) to $9 from $8 and keeps a Buy rating on the shares. The company announced positive topline results from Haduvio’s human abuse potential study, the analyst tells investors in a research note. The firm views the data as a “de-risking event,” saying it now has increased conviction that the drug is likely to show a positive risk-reward in idiopathic pulmonary fibrosis or third-line refractory chronic cough populations with critical unmet need.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRVI:
- Trevi Therapeutics selloff on data unwarranted, says H.C. Wainwright
- Trevi Therapeutics announces results from HAP study of oral nalbuphine
- Trevi Therapeutics Reports Q3 2024 Progress and Financials
- Trevi Therapeutics reports Q3 EPS (13c), consensus (12c)
- Stifel says Trevi’s RIVER enrollment completion puts data release in Q1 2025